Ciphaler
* Click to view the content
1. Comparative in-vitro performance evaluation of
formoterol/budesonide combination delivered through a novel multi-dose
dry powder inhaler versus unit-dose dry powder inhaler (NAPCON Delhi
and NAPCON Hyderabad 2023)
2. Comparative in vitro evaluation of two multi-dose dry powder
inhalers for delivery of formoterol/budesonide combination (NAPCON
Delhi and NAPCON Hyderabad 2023)
3. Usability and acceptability of Ciphaler™, a novel multi-dose DPI,
in patients with asthma or COPD: Results of a randomized, open-label,
cross-over trial (NAPCON Delhi 2023 and NAPCON Hyderabad 2023)
4. Comparative in-vitro performance evaluation of two fluticasone
furoate/ vilanterol/umeclidinium (100/25/62.5 mcg) multi-dose dry
powder inhalers (ERS Congress 2025, NAPCON Jaipur 2025)
5. Comparative in-vitro performance evaluation of two fluticasone
furoate/ vilanterol/umeclidinium (100/25/62.5 mcg) multi-dose dry
powder inhalers (NAPCON 2025 Pune/Coimbatore)
6. Comparative In-vitro Performance Evaluation of Two
Salmeterol/Fluticasone (50/250mcg) Multidose Discrete Dry Powder
Inhalers (NAPCON 2023 Hyderabad/Delhi)
7. Impact of incorrect inclination angle during inhalation on drug
delivery from a new discrete multi-dose dry powder inhaler (mDPI): An
in-vitro evaluation (ERS 2025; NAPCON Jaipur 2025)
8. Dose emission following accidental double activation of a novel
discrete multi-dose dry powder inhaler (mDPI): An In-vitro Evaluation
(NAPCON Jaipur 2025)